MP79-05 NEOADJUVANT APALUTAMIDE (ARN-509) AND RADICAL PROSTATECTOMY IN TREATMENT OF INTERMEDIATE TO HIGH RISK PROSTATE CANCER (NEAR) PHASE II TRIAL

INTRODUCTION AND OBJECTIVE:Apalutamide (ARN-509) exert near total antagonist activity at androgen receptors and is approved for treatment of M0 CRPC. ARN-509 as neoadjuvant treatment in organ confi...